Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
about
Cardiovascular gene therapy for myocardial infarctionRituximab in autoimmune diseasesSerious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.Infection risk in patients on multiple sclerosis therapeutics.Rituximab for nephrotic syndrome in children.A meta-analysis to determine the efficacy and tolerability of anti-B-cell monoclonal antibodies in multiple sclerosisRisk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsNovel applications of Rituximab in dermatological disordersRituximab in primary Sjögren's syndrome: a ten-year journey.Safety of monoclonal antibodies for the treatment of multiple sclerosis.Renal involvement in autoimmune connective tissue diseases.Rituximab for troublesome cases of childhood nephrotic syndrome.Rituximab Treatment for Nephrotic Syndrome in ChildrenB cells and autoimmunity.Successful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic NeuropathyRituximab in idiopathic membranous nephropathy.Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysisNovel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus.Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.Rituximab for autoimmune blistering diseases: recent studies, new insights.Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report.B Cell in Autoimmune Diseases.B-cell-depleting therapy in systemic lupus erythematosus.Setting the target for pemphigus vulgaris therapy.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Biologics in oral medicine: Sjogren syndrome.CD22 and autoimmune disease.Monoclonal antibodies in treatment of multiple sclerosis.Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.Multiple sclerosis treatment and infectious issues: update 2013.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.Treating the Underlying Pathophysiology of Primary Sjögren Syndrome: Recent Advances and Future Prospects.Anti-CD20 monoclonal antibodies in multiple sclerosis.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.[Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry].
P2860
Q27014770-AAE6260F-64C6-4EA5-879F-371D94D5C591Q28076091-3ACF1B8B-F7A9-4784-AF06-695F64CCCF44Q30731527-950C9F27-454A-4E3F-ADB2-81DE6E1F30D7Q30908652-9B014A68-1759-47EE-9D78-C9743A3BFF4DQ33555088-52295A5A-ABE1-469E-96EC-0EC20E8F4D46Q33744039-1083865D-3855-434C-81EE-145D30A6F061Q33757203-754353E0-9E01-4B1D-A964-D1613588D718Q33809045-00694FAB-A94F-4B2E-90C8-0218B584BD10Q34087599-8C6AA2D5-C35A-497B-BD14-CDAAF3B7BCEDQ34432465-BFF8E6DE-C73F-495D-B580-797C9C6C9C86Q34542922-6CF0D06B-6A70-4348-89F9-F22C2F874482Q34654954-1463C741-9FF7-4B69-A11F-C4B9C6AC3234Q34683518-76C63600-9C93-4C90-80EF-A8A4643FCC34Q35113681-2319EC15-965A-4A39-A819-55A194C9324FQ35706966-0BC073B2-1506-44DA-80EE-5E5D1BFD59C5Q35725735-0BB762FE-158A-4769-AE3B-0D7860919EF0Q36109197-18A2E62D-1117-426A-92F0-164EF22D6721Q36219954-BC04B4B2-783B-47C7-BBB1-2940EB14B096Q36278027-873AA3C9-4795-40D0-82E7-B87B78E1921AQ36394613-C69C1394-57FB-429F-A07E-C443D5517444Q36469965-19BC5610-4629-456F-9816-AB98B49D918CQ36727762-DD006B04-C47D-47EB-B662-D75836B75D5FQ36751954-A72B6EF0-F51C-4568-BC2F-1406A7FBE33DQ36929977-E8F16AE2-BA85-4E9F-9CB1-39B539DD5DC1Q36954468-E6AF87C1-A106-40D0-9420-9C0C70198A37Q37586344-CDD15897-79D0-4232-AC55-64A8E3078EBDQ37677416-D9B668AA-45D8-4406-90A0-5024EE98571FQ37954539-2F3D9EA3-CC56-43CD-BD8E-4B41E07F31DCQ38002156-7387BF0C-F50C-4601-84BE-44863BFBDDB8Q38053491-40E55EBF-4B5B-404B-B5CA-746621ED1401Q38133865-46E8A811-07BD-4A52-A61C-5C2F5CC5B443Q38149856-534CFC5D-4E45-433A-A0E2-702E80514204Q38153471-418C6A95-E674-4C31-BA49-B5F53DB18EF2Q38286209-A23B8F40-84D2-4E47-8109-65E6BEEDA815Q38569860-A1EDF4FA-3476-456F-BFDD-2345D7CB600AQ38795404-87C4ECCB-A17A-42BF-9BD4-B6E097887BADQ38975695-43D80398-56C3-4A72-B26E-1BBE47215358Q38979169-90796E2D-355A-41AF-B7DA-45D6CE64A4BBQ39440837-3803CC2F-4B3A-448C-B4F8-B4493CA613BEQ40201287-C878660A-14CA-4D91-896F-9B8FC587FB6C
P2860
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Safety and clinical outcomes o ...... m a national registry (GRAID).
@ast
Safety and clinical outcomes o ...... m a national registry (GRAID).
@en
type
label
Safety and clinical outcomes o ...... m a national registry (GRAID).
@ast
Safety and clinical outcomes o ...... m a national registry (GRAID).
@en
prefLabel
Safety and clinical outcomes o ...... m a national registry (GRAID).
@ast
Safety and clinical outcomes o ...... m a national registry (GRAID).
@en
P2093
P2860
P50
P356
P1476
Safety and clinical outcomes o ...... m a national registry (GRAID).
@en
P2093
Andrea Rubbert-Roth
Andreas Schwarting
Anna L Herzog
Christof Specker
Christoph Fiehn
Claudia Metzler
Cornelia Erfurt-Berge
Elvira Schmidt
Enno Schmidt
Florian M P Meier
P2860
P2888
P356
10.1186/AR3337
P50
P577
2011-05-13T00:00:00Z
P5875
P6179
1033386484